Peterson, P K, Shepard, J, Macres, M et al. · The American journal of medicine · 1990 · DOI
Researchers tested whether a blood product called intravenous immunoglobulin G (IV IgG) could help people with ME/CFS by giving it to 28 patients every month for 6 months. Although some patients had low levels of this protein at the start, IV IgG did not improve fatigue, daily functioning, or overall health compared to placebo, even though the treatment restored protein levels to normal.
This high-quality trial is important because it tested a plausible immunologic hypothesis in ME/CFS and rigorously evaluated whether correcting documented immune abnormalities (low immunoglobulin subclasses) could improve clinical outcomes. The negative result helped redirect research efforts toward understanding the underlying mechanisms of ME/CFS rather than empirical immune replacement therapy.
This study does not prove that immune abnormalities play no role in ME/CFS pathogenesis, only that correcting one type of abnormality (IgG subclass deficiency) with this specific intervention does not improve symptoms. It also does not address whether other immune-modulating therapies or treatments targeting different immune pathways might be beneficial.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →